Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Argus from a “buy” rating to a “hold” rating in a report released on ...

StockNews.com upgraded shares of Capital Southwest (NASDAQ:CSWC – Free Report) from a sell rating to a hold rating in a report issued on Thursday morning. Capital Southwest Stock Performance Shares of ...

Cognyte Software (NASDAQ:CGNT – Get Free Report) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on ...

Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research report issued on Friday. Other equities research analysts ...

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) had its price objective upped by equities researchers at HC Wainwright from $10.00 to $24.00 in a research report issued on Friday,Benzinga reports ...

Biogen (NasdaqGS:BIIB) recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, ...